Bromodomain Containing Protein 2 – Pipeline Review, H1 2020

Global Markets Direct’s, ‘Bromodomain Containing Protein 2 (Really Interesting New Gene 3 Protein or O27.1.1 or BRD2) – Pipeline Review, H1 2020’, provides in depth analysis on Bromodomain Containing Protein 2 (Really Interesting New Gene 3 Protein or O27.1.1 or BRD2) targeted pipeline therapeutics. The report provides comprehensive information complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Bromodomain Containing Protein 2 (Really Interesting New Gene 3 Protein or O27.1.1 or BRD2) targeted therapeutics development and features dormant and discontinued projects. The report analyses the pipeline products from therapy areas Oncology, Dermatology, Immunology, Musculoskeletal Disorders and Respiratory under development targeting Bromodomain Containing Protein 2 (Really Interesting New Gene 3 Protein or O27.1.1 or BRD2).

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

*Updated report will be delivered in 48 hours of order confirmation.

Scope

– The report provides a snapshot of the global therapeutic landscape for Bromodomain Containing Protein 2 (Really Interesting New Gene 3 Protein or O27.1.1 or BRD2)

– The report reviews Bromodomain Containing Protein 2 (Really Interesting New Gene 3 Protein or O27.1.1 or BRD2) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

– The report reviews key players involved in Bromodomain Containing Protein 2 (Really Interesting New Gene 3 Protein or O27.1.1 or BRD2) targeted therapeutics and enlists all their major and minor projects

– The report assesses Bromodomain Containing Protein 2 (Really Interesting New Gene 3 Protein or O27.1.1 or BRD2) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

– The report summarizes all the dormant and discontinued pipeline projects

– The report reviews latest news and deals related to Bromodomain Containing Protein 2 (Really Interesting New Gene 3 Protein or O27.1.1 or BRD2) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand the targeted therapy areas and indications for Bromodomain Containing Protein 2 (Really Interesting New Gene 3 Protein or O27.1.1 or BRD2)

- Identify the use of drugs for target identification and drug repurposing

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Bromodomain Containing Protein 2 (Really Interesting New Gene 3 Protein or O27.1.1 or BRD2) development landscape

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Companies mentioned

AbbVie Inc

Amgen Inc

Boston Pharmaceuticals Inc

Bristol-Myers Squibb Co

Constellation Pharmaceuticals Inc

Ningbo Wenda Pharma

Zenith Epigenetics Ltd

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Bromodomain Containing Protein 2 (Really Interesting New Gene 3 Protein or O27.1.1 or BRD2) – Overview

Bromodomain Containing Protein 2 (Really Interesting New Gene 3 Protein or O27.1.1 or BRD2) – Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

Bromodomain Containing Protein 2 (Really Interesting New Gene 3 Protein or O27.1.1 or BRD2) – Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Bromodomain Containing Protein 2 (Really Interesting New Gene 3 Protein or O27.1.1 or BRD2) – Companies Involved in Therapeutics Development

AbbVie Inc

Amgen Inc

Boston Pharmaceuticals Inc

Bristol-Myers Squibb Co

Constellation Pharmaceuticals Inc

Ningbo Wenda Pharma

Zenith Epigenetics Ltd

Bromodomain Containing Protein 2 (Really Interesting New Gene 3 Protein or O27.1.1 or BRD2) – Drug Profiles

ABBV-744 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BOS-475 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CC-95775 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CPI-0610 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NHWD-870 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NUE-19796 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NUE-20798 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NUE-7770 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

QCA-570 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ZEN-3694 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Bromodomain Containing Protein 2 (Really Interesting New Gene 3 Protein or O27.1.1 or BRD2) – Dormant Products

Bromodomain Containing Protein 2 (Really Interesting New Gene 3 Protein or O27.1.1 or BRD2) – Discontinued Products

Bromodomain Containing Protein 2 (Really Interesting New Gene 3 Protein or O27.1.1 or BRD2) – Product Development Milestones

Featured News & Press Releases

Jan 07, 2020: Zenith Epigenetics receives US$5 million milestone payment from Newsoara

Dec 19, 2019: Zenith Epigenetics announces clinical advancement of ZEN-3694

Dec 09, 2019: Constellation Pharmaceuticals provides updated preliminary data from MANIFEST clinical trial with CPI-0610 in oral and poster presentations at ASH

Dec 02, 2019: Constellation Pharmaceuticals to host analyst/investor meeting at ASH to discuss updated preliminary data from the MANIFEST clinical trial with CPI-0610

Nov 06, 2019: FORMA announces poster presentation on FT-1101 at upcoming 2019 ASH Annual Meeting

Oct 10, 2019: Constellation Pharmaceuticals announces MANIFEST data updates will be provided in oral and poster sessions on December 9 at ASH

Jun 27, 2019: Zenith Epigenetics announces dosing of first patient in triple negative breast cancer trial with Pfizer

Jun 03, 2019: Interim data for CPI-0610 in MANIFEST clinical trial showed signals of clinical activity in Myelofibrosis patients

May 23, 2019: Constellation Pharmaceuticals to Host Analyst/Investor Meeting at ASCO to Discuss Interim Update of Data of CPI-0610 in MANIFEST Clinical Trial

May 16, 2019: Constellation Pharmaceuticals provides interim update of data for CPI-0610 in ASCO and EHA abstracts

May 09, 2019: Nuevolution’s BET-BD1 selective inhibitor and candidate compound, NUE20798, shows positive effect on disease scoring and biomarker levels in an atopic dermatitis (eczema) mouse model

Mar 18, 2019: Zenith Epigenetics announces U.S. FDA clearance of investigational new drug application for ZEN-3694 in TNBC program

Feb 21, 2019: A Nuevolution BET-BD1 selective inhibitor shows potential anticancer effect with immunotherapy in a mouse model of colorectal cancer

Jan 03, 2019: Constellation Pharmaceuticals provides update on MANIFEST clinical trial of CPI-0610 in mlyelofibrosis

Nov 01, 2018: Constellation Pharmaceuticals receives FDA Fast Track Designation for CPI-0610 in treatment of Myelofibrosis

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development by Stage of Development, H1 2020

Number of Products under Development by Therapy Areas, H1 2020

Number of Products under Development by Indications, H1 2020

Number of Products under Development by Indications, H1 2020 (Contd..1), H1 2020

Number of Products under Development by Companies, H1 2020

Products under Development by Companies, H1 2020

Products under Development by Companies, H1 2020 (Contd..1), H1 2020

Products under Development by Companies, H1 2020 (Contd..2), H1 2020

Number of Products under Investigation by Universities/Institutes, H1 2020

Products under Investigation by Universities/Institutes, H1 2020

Number of Products by Stage and Mechanism of Actions, H1 2020

Number of Products by Stage and Route of Administration, H1 2020

Number of Products by Stage and Molecule Type, H1 2020

Pipeline by AbbVie Inc, H1 2020

Pipeline by Amgen Inc, H1 2020

Pipeline by Boston Pharmaceuticals Inc, H1 2020

Pipeline by Bristol-Myers Squibb Co, H1 2020

Pipeline by Constellation Pharmaceuticals Inc, H1 2020

Pipeline by Ningbo Wenda Pharma, H1 2020

Pipeline by Zenith Epigenetics Ltd, H1 2020

Dormant Products, H1 2020

Dormant Products, H1 2020 (Contd..1), H1 2020

Discontinued Products, H1 2020

List of Figures

List of Figures

Number of Products under Development by Stage of Development, H1 2020

Number of Products under Development by Therapy Areas, H1 2020

Number of Products under Development by Top 10 Indications, H1 2020

Number of Products by Stage and Mechanism of Actions, H1 2020

Number of Products by Routes of Administration, H1 2020

Number of Products by Stage and Routes of Administration, H1 2020

Number of Products by Stage and Molecule Type, H1 2020

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports